SKYSCRAPER-02: Phase III Trial of First-line Atezolizumab + Carboplatin/Etoposide ± Tiragolumab, an Anti-TIGIT Antibody, in ES-SCLC

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
The phase III SKYSCRAPER-02 trial showed no additional benefit with tiragolumab added to first-line atezolizumab plus carboplatin/etoposide in ES-SCLC.
Format: Microsoft PowerPoint (.ppt)
File Size: 341 KB
Released: June 9, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings